Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis.
The incidence and the degree of uremic hypertriglyceridemia in a hemodialysis population are exacerbated by the use of UF heparin as anticoagulant therapy. This hypertriglyceridemia is associated with an increase in the levels of triglyceride-rich remnant particles that are thought to be particularly atherogenic. Since arteriosclerosis and its related diseases are the major causes of morbidity and mortality in this dialysis population, the LMW heparins with their reduced stimulation of plasma lipolytic activity may provide a clinically superior alternative to UF heparin for anticoagulation therapy in long-term hemodialysis. One may also speculate that it may be more advantageous to use LMW heparin for all long-term treatments with heparin.
Schrader
J
J
Department of Nephrology, University Clinic, Göttingen, FRG.
Andersson
L O
LO
Armstrong
V W
VW
Kundt
M
M
Stibbe
W
W
Scheler
F
F
D006493:Heparin / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced; D008066:Lipolysis / Q000187:drug effects*; D006435:Renal Dialysis
D006495:Heparin, Low-Molecular-Weight; D006493:Heparin